PEGASUS-TIMI 54 study shows that long-term treatment with BRILINTA reduced thrombotic cardiovascular events in patients with a history of heart attack
|
16 March 2015 |
AstraZeneca completes acquisition of rights to Actavis’ branded respiratory portfolio in the US and Canada
|
03 March 2015 |
AstraZeneca to acquire rights to Actavis’ branded respiratory portfolio in the US and Canada
|
05 February 2015 |
AstraZeneca announces collaborations to use CRISPR technology for genome editing across its drug discovery platform
|
29 January 2015 |
MedImmune enters licensing agreement with Omnis Pharmaceuticals for oncolytic viruses in immuno-oncology
|
12 January 2015 |
Jury verdict favours AstraZeneca in Nexium antitrust litigation
|
05 December 2014 |
Amgen and AstraZeneca announce positive results from third and final pivotal Phase III study of Brodalumab in patients with moderate-to-severe plaque psoriasis
|
27 November 2014 |
AstraZeneca announces initiation of development programme for BRILINTA® reversal agent
|
13 November 2014 |
AstraZeneca launches Healthy Heart Africa programme to address hypertension in Africa
|
29 October 2014 |
AstraZeneca strengthens partnership with the University of Cambridge
|
27 October 2014 |